Due to the actions of a 3rd party, our laboratory software is unable to process orders at our normal capacity. This is not a data breach. If this affects your laboratory orders, we will contact you directly. You do not need to call the practice.

Clinical Trials & Research

20137 - PH3 Atez Tira Dura Sg 3 NSCLC

GO41854: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)

Disease Types: Lung (Non Small Cell),&nbs

Available at: {clinical_trial_location backspace="7"}20137 - PH3 Atez Tira Dura Sg 3 NSCLC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}